Literature DB >> 19473378

Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management.

G Zeppetella1.   

Abstract

Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for managementBreakthrough pain is a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain. The onset of breakthrough pain is typically fast and the duration is usually relatively short, but despite the self-limiting nature of each breakthrough pain, the repeated episodes can have a significant impact on patients' quality of life. Effective management is therefore imperative and often involves the use of supplemental doses of medication known as 'rescue medication'. The ideal rescue medication should be efficacious, have a rapid onset of action, a relatively short duration of effect and minimal adverse effects. Normal-release oral opioids have been the mainstay approach for patients who are receiving around the clock opioid regimen, but the onset and duration of action of oral opioids such as morphine may not be suitable for treating many breakthrough pains.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19473378     DOI: 10.1111/j.1365-2354.2008.01009.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  7 in total

Review 1.  Pharmacotherapy for breakthrough cancer pain.

Authors:  Sebastiano Mercadante
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

2.  Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain.

Authors:  Sebastiano Mercadante; Renato Vellucci; Arturo Cuomo; Claudio Adile; Andrea Cortegiani; Alessandro Valle; Patrizia Villari; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2014-10-29       Impact factor: 3.603

Review 3.  Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice.

Authors:  Paolo Bossi; Yolanda Escobar; Federico Pea
Journal:  Front Pain Res (Lausanne)       Date:  2022-05-26

Review 4.  A comprehensive review of rapid-onset opioids for breakthrough pain.

Authors:  Howard Smith
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

5.  Considerations in selecting rapid-onset opioids for the management of breakthrough pain.

Authors:  Howard S Smith
Journal:  J Pain Res       Date:  2013-03-06       Impact factor: 3.133

6.  Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain.

Authors:  Josep Darbà; Lisette Kaskens; Rainel Sánchez-de la Rosa
Journal:  Clinicoecon Outcomes Res       Date:  2013-12-16

Review 7.  Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.

Authors:  Furio Zucco; Cesare Bonezzi; Diego Fornasari
Journal:  Adv Ther       Date:  2014-07-09       Impact factor: 3.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.